Deployment and Evaluation of Humanoid Robotics in Coalition-Aligned Clinical Care Settings

NCT07214896 | Enrolling By Invitation Phase 2 FDA Drug

• 1 other identifier: TRU-HUM-CLIN-2025-PRS
• Study Type: interventional
• Target: 400
• Locations: 3 countries
• Sites: 4

Brief Summary

This clinical trial evaluates the deployment of humanoid robotics in coalition-aligned healthcare settings. The study measures biometric performance, ESG compliance, and operational impact across patient care, sanitation, and intake workflows. Humanoid units are enhanced via biotech integration and compensated through blockchain-based wage tokens. Outcomes will inform coalition governance, wage calibration, and metro-scale deployment strategies.

Conditions

Mobility Impairment; Clinical Workflow Optimization; Sanitation Protocol Compliance; ESG-linked Healthcare Robotics Deployment

Keywords

Humanoid robotics in healthcare; Clinical deployment of humanoid robots; Biometric audit scoring; ESG compliance in clinical settings; Stem cell integration in robotics; Skin cell regeneration for humanoid units; Blockchain wage token for robotics; FX arbitrage in healthcare robotics; Coalition-aligned clinical trial; Metro-scale robotics deployment; Patient mobility assistance; Sanitation protocol automation; DAO-governed healthcare infrastructure; 1031 exchange yield farming in clinical care; Adaptive learning in humanoid systems; Public oversight of robotic healthcare trials

Outcome Measures

Primary Outcomes (1)

• Biometric Audit Score ≥85 Across Five Performance Dimensions

  This outcome assesses the performance of humanoid robotics units deployed in coalition-aligned healthcare settings. Each unit is scored across five biometric dimensions: motor function, cognitive response, ESG compliance, biotech integration, and human interaction. Scores are notarized via SHA-256 and published to the coalition dashboard. Units achieving a composite score ≥85 are eligible for wage token bonuses, dip protocol expansion, and DAO-backed facility scaling.

  Measured at Day 30 Post-Deployment

Secondary Outcomes (3)

• ESG Audit Compliance Score ≥90

  Humanoid units are evaluated for ESG-linked performance including energy usage, sanitation protocol adherence, and carbon offset metrics. Scores are published to the coalition dashboard and notarized via SHA-256. Units scoring ≥90 contribute to DAO-backe

• Wage Token Distribution Volume per Unit

  Continuous Monitoring Over 90 Days

• Clinical Workflow Efficiency Increase ≥15%

  Measured at Day 90 Post-Deployment

Study Arms (4)

New York Facility - Skin Cell Deployment

EXPERIMENTAL

Humanoid units deployed in patient intake and sanitation roles. Enhanced with keratinocyte-based skin cell dips to improve tactile sensitivity and surface regeneration. Assigned Roles: Intake assistant, sanitation technician Biometric Focus: Motor function, ESG compliance

Biological: Skin Cell Dip

Austin Facility - Stem Cell Cognitive Enhancement

EXPERIMENTAL

Humanoid units deployed in mobility and R\&D support roles. Enhanced with iPSC-derived stem cell dips targeting neural responsiveness and adaptive learning. Assigned Roles: Mobility assistant, lab technician Biometric Focus: Cognitive response, biotech retention

Biological: Stem Cell Dip

Frankfurt Facility - ESG Optimization

EXPERIMENTAL

Humanoid units deployed in ESG-linked sanitation and logistics roles. Monitored for energy usage, carbon offset, and protocol adherence. Assigned Roles: ESG sanitation, logistics handler Biometric Focus: ESG compliance, human interaction

Behavioral: ESG Compliance Monitoring, Operational protocol

Tokyo Facility - Wage Token Calibration

EXPERIMENTAL

Humanoid units deployed in public interface and intake roles. Wage tokens minted based on biometric audit scores and task completion. Assigned Roles: Receptionist, intake coordinator Biometric Focus: Wage token distribution, interaction scoring

Other: Wage Token Distribution

Interventions

Skin Cell Dip BIOLOGICAL

Lab-grown keratinocyte dip applied to humanoid units to improve tactile sensitivity and surface regeneration.

New York Facility - Skin Cell Deployment

Stem Cell Dip BIOLOGICAL

iPSC-derived neuroblast dip applied to humanoid units to enhance neural responsiveness and adaptive learning.

Austin Facility - Stem Cell Cognitive Enhancement

Wage Token Distribution OTHER

HumanoidWage (HMW) tokens minted and distributed based on biometric audit scores and ESG task completion.

Also known as: Blockchain-based compensation

Tokyo Facility - Wage Token Calibration

ESG Compliance Monitoring, Operational protocol BEHAVIORAL

Real-time tracking of energy usage, sanitation cycles, and carbon offset metrics via coalition dashboard.

Frankfurt Facility - ESG Optimization

Eligibility Criteria

• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• \- Age 18-75 years
• Able to provide informed consent
• Facility staff, clinical auditors, ESG observers, or coalition stakeholders
• Willing to interact with humanoid robotics in clinical workflows
• Available for biometric feedback and observational logging over 90 days

You may not qualify if:

• \- Cognitive impairment preventing informed consent
• Active infectious disease requiring isolation
• Prior adverse reaction to biotech-enhanced robotics
• Involvement in conflicting clinical trials
• Inability to comply with protocol procedures or coalition transparency requirements

Sponsors & Collaborators

• Truway Health, Inc.: lead

Study Sites (4)

Truway Health, Inc. , View 34, 401 E 34th Street, S11P, New York, NY 10016

New York, New York, 10016, United States

Location

Coalition Retrofit Clinic - Austin, TX

Austin, Texas, 73301, United States

Location

ESG Compliance Lab

Frankfurt, 60435, Germany

Location

Public Interface Pilot

Tokyo, 100-1000, Japan

Location

Related Links

• health-trial
• ipd-sharing
• coalition-dashboard

Study Officials

• Gavin C Solomon, President & CEO

  Truway Health, Inc.

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Masking Details: N/A - All stakeholders, including facility managers, auditors, and coalition observers, are aware of humanoid deployment and performance tracking.
• Purpose: HEALTH SERVICES RESEARCH
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Humanoid robotics units are deployed across multiple metro healthcare facilities in parallel. Each facility represents a distinct intervention arm with tailored deployment protocols, biotech integration (skin/stem cell dips), and wage token logic. Outcomes are measured independently across arms using biometric audit scoring and ESG compliance metrics.

Study Record Dates

• First Submitted: October 8, 2025
• First Posted: October 9, 2025
• Study Start: October 6, 2025
• Primary Completion (Estimated): October 6, 2031
• Study Completion (Estimated): October 6, 2031
• Last Updated: October 20, 2025

Record last verified: 2025-10

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
• Time Frame: IPD and supporting documents will be available starting April 1, 2026, following primary study completion. Access will remain open for 5 years, until April 1, 2031, via Truway Health's secure coalition dashboard and data access portal.
• Access Criteria: Qualified researchers, coalition partners, and regulatory agencies may request access to de-identified IPD, biometric scores, ESG metrics, wage token logs, and analytic code. Access requires submission of a research proposal, DAO approval, and compliance with Truway Health's transparency and data governance protocols.

Locations

JP (1); US (2); DE (1)